Online inquiry

IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5953MR)

This product GTTS-WQ5953MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Allergic diseases research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5953MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13889MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ6790MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DS-8201
GTTS-WQ6563MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ11008MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ5908MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ10569MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ14453MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ6969MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW